Revolution Medicines (RVMD) Stock Falls as Merck Walks Away From Takeover Deal

TLDR Revolution Medicines and Merck ended acquisition talks due to price disagreements The proposed deal was reportedly valued between $28 billion and $32 billion Revolution Medicines stock fell after the breakdown in negotiations was reported The company’s experimental cancer drug daraxonrasib was a key asset in the potential deal Some investors see the failed talks [...]

The post Revolution Medicines (RVMD) Stock Falls as Merck Walks Away From Takeover Deal appeared first on Blockonomi.